Quizartinib Combination Therapy Shows Promise in Phase II Trial for FLT3-ITD AML
核心洞察
A phase II trial evaluated the combination of quizartinib and omacetaxine mepesuccinate in patients with FLT3-ITD (搜索) acute myeloid leukemia, building on previous research showing potential synergy between these agents.
The study addresses resistance mechanisms to FLT3 (搜索) inhibitors, including bone marrow microenvironment-mediated resistance and metabolic dependencies in FLT3-ITD (搜索)-driven AML cells.
Research findings highlight the importance of targeting multiple pathways simultaneously, as FLT3-ITD (搜索) mutations represent about 80% of all FLT3 (搜索) mutations and are associated with increased relapse risk and shorter overall survival.
A new phase II clinical trial is investigating the combination of quizartinib and omacetaxine mepesuccinate for treating patients with FLT3-ITD (搜索) acute myeloid leukemia (AML), representing a novel approach to overcome resistance mechanisms that limit the effectiveness of single-agent FLT3 (搜索) inhibitor therapy.
Targeting FLT3-ITD Mutations in AML
FLT3-ITD (搜索) mutations occur in approximately one-third of newly diagnosed AML cases and represent about 80% of all FLT3 (搜索) mutations. These mutations are considered driver mutations associated with increased risk of relapse and shorter overall survival compared to other AML subtypes. The discovery of the FLT3 gene mutation over 20 years ago led to the development of FLT3 inhibitor therapies that are now approved for clinical use in different treatment settings.
Dr. Harry P. Erba, Professor of Medicine at Duke Cancer Institute, emphasizes the importance of FLT3 (搜索) testing: "It is recommended that FLT3 testing be performed at diagnosis in all patients with acute myeloid leukemia. Understanding the FLT3 mutation type helps predict disease behavior and guide the selection of mutation-specific therapies."
Addressing Resistance Mechanisms
The combination approach being studied addresses several known resistance mechanisms to FLT3 (搜索) inhibitors. Research has identified that bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD (搜索) AML is mediated by persistent activation of extracellular regulated kinase. Additionally, studies have shown that FLT3 ligand can impede the efficacy of FLT3 inhibitors both in vitro and in vivo.
Previous research by Lam et al. demonstrated that homoharringtonine (omacetaxine mepesuccinate) could serve as an adjunct for FLT3-ITD (搜索) acute myeloid leukemia, providing the scientific rationale for the current combination study. The mechanism involves targeting chaperon protein HSP70 (搜索), which has been identified as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia.
Metabolic Vulnerabilities in FLT3-ITD AML
Recent research has uncovered several metabolic dependencies in FLT3-ITD (搜索)-driven AML that may be exploited therapeutically. Studies have shown that serine biosynthesis represents a metabolic vulnerability in FLT3-ITD-driven acute myeloid leukemia, while glutaminolysis has been identified as a metabolic dependency that is unmasked by FLT3 (搜索) tyrosine kinase inhibition.
The mTOR (搜索) signaling pathway is activated by FLT3 (搜索) kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells, suggesting additional therapeutic targets. Furthermore, PDP1 (搜索) has been identified as a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD (搜索)-positive acute myeloid leukemia.
Current Treatment Landscape
Quizartinib (VANFLYTA) is currently the only FLT3 (搜索) inhibitor FDA-approved for use across all three treatment phases - induction, consolidation, and maintenance therapy - for patients with newly diagnosed FLT3-ITD (搜索)+ AML. The approval was based on results from the QuANTUM-First trial, which was the largest and longest trial of patients with newly diagnosed FLT3-ITD+ AML.
The NCCN Clinical Practice Guidelines include specific recommendations for quizartinib use, listing it as a Category 1 treatment option for eligible patients with FLT3-ITD (搜索)+ AML for intensive induction in combination with standard 7+3 chemotherapy, and as a Category 2A recommendation for consolidation and maintenance therapy.
Clinical Implications
The phase II combination trial represents an important step in addressing the challenge of resistance to FLT3 (搜索) inhibitor monotherapy. With an estimated 22,720 new cases of AML to be diagnosed in the US in 2026 and a five-year relative survival rate of approximately 32.9%, novel therapeutic approaches are critically needed.
The study builds on growing understanding of the complex biology underlying FLT3-ITD (搜索) AML, including the role of leukemia stem cells and the bone marrow microenvironment in treatment resistance. Single-cell RNA sequencing studies have revealed AML hierarchies relevant to disease progression and immunity, providing insights into chemoresistant properties in leukemic stem and progenitor cells.
As Dr. Erba notes, "The treatment setting, clinical data and other factors are also important to selecting a FLT3 (搜索) inhibitor," highlighting the need for personalized treatment approaches based on individual patient characteristics and disease biology.